Recent Updates
Recently added Catalysts
CARM Positive Sentiment Score: 75/100

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Wednesday, February 19, 2025 1 min read
Key Takeaway: Carisma Therapeutics Inc. will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025. Michael Klichinsky, Co-founder and Chief Scientific Officer, is set to represent the company. The event will be accessible via an audio webcast, highlighting Carisma's commitment to advancing macrophage engineering in therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Carisma Therapeutics is participating in a notable industry conference.
  • The company is recognized as a leader in macrophage-focused therapeutics.
  • The event will showcase their innovative approaches to treatment.

Full Press Release Details

PHILADELPHIA,Feb. 19, 2025/PRNewswire/ --Carisma Therapeutics Inc.(Nasdaq:CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced thatMichael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rdAnnual Cell Therapy Virtual Conference onTuesday, February 25at10:30 am ET.
An audio webcast of the event will be available on the Company'sInvestor Eventssection of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visitwww.Carismatx.com.

Investors:Shveta Dighe[email protected]

Media Contact:Julia Stern(763) 350-5223[email protected]

SOURCE Carisma Therapeutics Inc.

Frequently Asked Questions

When is the H.C. Wainwright Conference?

The conference is scheduled for February 25, 2025.

Who will represent Carisma at the conference?

Michael Klichinsky, Co-founder and Chief Scientific Officer, will represent Carisma.

How can I access the conference audio webcast?

The audio webcast will be available on Carisma's Investor Relations webpage.

What is Carisma Therapeutics focused on?

Carisma focuses on macrophage engineering for therapies targeting various diseases.

Tags: CARM Viatris Investor Conferences Healthcare Carisma Therapeutics H.C. Wainwright cell therapy macrophage therapeutics biopharmaceutical
Last updated: Feb 19, 2025